LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes.

Trial Profile

LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Branch retinal vein occlusion; Central retinal vein occlusion; Diabetic macular oedema; Wet age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LUMINOUS
  • Sponsors Novartis; Novartis Ophthalmics; Novartis Pharmaceuticals
  • Most Recent Events

    • 20 May 2016 Status changed from recruiting to completed.
    • 03 Mar 2016 Planned number of patients changed from 26146 to 30000 as reported by ClinicalTrials.gov.
    • 03 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top